Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 12/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 5/20 | 0.41 |
| ▸ | CASP9 | P55211 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598767 | 0.91 | CASP1 (0.54) | CASP1CASP3CASP7CASP9CASP4 | |
| SCHEMBL7415849 | 0.90 | CASP1 (0.61) | CASP1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL7413096 | 0.90 | CASP1 (0.61) | CASP1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL7419914 | 0.83 | CASP1 (0.56) | CASP1MMP1MMP2MMP9MMP8 | |
| SCHEMBL7420318 | 0.82 | CASP3 (0.45) | CASP1CASP3CASP7CASP9ELANE | |
| SCHEMBL7383726 | 0.81 | CASP1 (0.56) | CASP1MMP1MMP2MMP9MMP8 | |
| SCHEMBL7379431 | 0.80 | CASP1 (0.75) | CASP1CASP3CASP7CASP9CASP4 | |
| SCHEMBL6159612 | 0.79 | CASP1 (0.58) | CASP1MMP1MMP2MMP9MMP8 | |
| SCHEMBL6160169 | 0.78 | CASP1 (0.78) | CASP1MMP1MMP2MMP9MMP8 | |
| SCHEMBL6158160 | 0.78 | CASP1 (0.63) | CASP1MMP1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946502-B1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | claimed |
| US-6316415-B1 | INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | claimed |
| EP-0946502-A1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998016505-A1 | SULFONAMIDE INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0946502-B1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6316415-B1 | INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1R1 | CASP1 11/4885MMP1 97/4885MMP2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.